Robert Andrade
Insider (Form 4 reporting owner): CHIEF FINANCIAL OFFICER CIK 1468308Name as filed: Andrade RobertIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 28 Dec 2022, sold $1.9M in 6 sales (4 under a 10b5-1 plan set in advance) of Fennec Pharmaceuticals.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Fennec Pharmaceuticals FENC | CHIEF FINANCIAL OFFICER | 28 Dec 2022 | 27 Aug 2026 | – | 6$1.9M |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | too few trades4 trades | too few trades4 trades | too few trades4 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 1 | $884K | -$884K |
| 2024 | – | – | 3 | $622K | -$622K |
| 2023 | – | – | 1 | $223K | -$223K |
| 2022 | – | – | 1 | $211K | -$211K |
Every trade
7, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 27 Aug 2026 | Fennec Pharmaceuticals FENC | Sellafter exercising options | 75,000 | $11.78 | $884K | 10b5-1 plan | Form 4filed 28 Aug 2026 |
| 1 Apr 2024 | Fennec Pharmaceuticals FENC | Buyprice as filed looks wrong; not counted | 0 | Not filed | Not filed | No | Form 4filed 3 Apr 2024 |
| 26 Mar 2024 | Fennec Pharmaceuticals FENC | Sell | 13,975 | $10.90 | $152K | No | Form 4filed 27 Mar 2024 |
| 25 Mar 2024 | Fennec Pharmaceuticals FENC | Sell | 13,975 | $11.00 | $154K | 10b5-1 plan | Form 4filed 25 Mar 2024 |
| 4 Jan 2024 | Fennec Pharmaceuticals FENC | Sell | 30,000 | $10.53 | $316K | 10b5-1 plan | Form 4filed 5 Jan 2024 |
| 28 Jun 2023 | Fennec Pharmaceuticals FENC | Sellafter exercising options | 25,000 | $8.93 | $223K | 10b5-1 plan | Form 4filed 30 Jun 2023 |
| 28 Dec 2022 | Fennec Pharmaceuticals FENC | Sell | 22,000 | $9.60 | $211K | Not stated | Form 4filed 30 Dec 2022 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.